The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta‐analysis
Open accessAbstract
Aim: The aim of the present study was to explore the impact of strategies to reduce polypharmacy on mortality, hospitalization and change in number of drugs. Methods: Systematic review and meta‐analysis: a systematic literature search targeting patients ≥65 years with polypharmacy (≥4 drugs), focusing on patient‐relevant outcome measures, was conducted. We included controlled studies aiming to reduce polypharmacy. Two reviewers independently assessed studies for eligibility, extracted data and evaluated study quality. Results: Twenty‐five studies, including 10 980 participants, were included, comprising 21 randomized controlled trials and four nonrandomized controlled trials. The majority of the included studies aimed at improving quality or the appropriateness of prescribing by eliminating inappropriate and non‐evidence‐based drugs. These strategies to reduce polypharmacy had no effect on all‐cause mortality (odds ratio 1.02; 95% confidence interval 0.84, 1.23). Only single studies found improvements, in terms of reducing the number of hospital admissions, in favour of the intervention group. At baseline, patients were taking, on average, 7.4 drugs in both the intervention and the control groups. At follow‐up, the weighted mean number of drugs was reduced (−0.2) in the intervention group but increased (+0.2) in controls. Conclusions: There is no convincing evidence that the strategies assessed in the present review are effective in reducing polypharmacy or have an impact on clinically relevant endpoints. Interventions are complex; it is still unclear how best to organize and implement them to achieve a reduction in inappropriate polypharmacy. There is therefore a need to develop more effective strategies to reduce inappropriate polypharmacy and to test them in large, pragmatic randomized controlled trials on effectiveness and feasibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Lenaghan, E., Holland, R., & Brooks, A. (2007) · Age and Ageing · doi:10.1093/ageing/afm036 · Cited by 182
Cited by
An update on the clinical consequences of polypharmacy in older adults: a narrative review
Wastesson, J. W., Morin, L., Tan, E. C. K., & Johnell, K. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1546841 · Cited by 617
Interventions to improve the appropriate use of polypharmacy for older people
Rankin, A., Cadogan, C. A., Patterson, S. M., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub4 · Cited by 511
The epidemiology of polypharmacy in older adults: register-based prospective cohort study
Morin, L., Johnell, K., Laroche, M.-L., Fastbom, J., & Wastesson, J. W. (2018) · Clinical Epidemiology · doi:10.2147/clep.s153458 · Cited by 376
Reeve, E., Thompson, W., & Farrell, B. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.12.021 · Cited by 331
Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
Delara, M., Murray, L., Jafari, B., Bahji, A., Goodarzi, Z., Kirkham, J., Chowdhury, M., & Seitz, D. P. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03279-x · Cited by 341
Metadata
- Authors
- Johansson, T., Abuzahra, M. E., Keller, S., Mann, E., Faller, B., Sommerauer, C., Höck, J., Löffler, C., Köchling, A., Schuler, J., Flamm, M., & Sönnichsen, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2016-05-07
- Volume
- 82
- Issue
- 2
- Pages
- 532-548
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2331606069
- Cited by
- 234
- References
- 3
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.